Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.

Presbyopia News

12/6/2024
BreakingEuropeIOLPresbyopiaRefractiveSurgical
Ophtec Receives CE Marking for Artiplus Phakic IOL, Targets Young Presbyopes
Ophtec Receives CE Marking for Artiplus Phakic IOL, Targets Young Presbyopes

Dutch company Ophtec announced Nov. 18 that it had gained CE Mark approval for its Artiplus phakic intraocular lens (IOL). The company said the lens offered a solution for relatively young presbyop...

11/14/2024
NewsletterPharmaPresbyopiaRegulation
US FDA Accepts NDA For Lenz’ Presbyopia Drop Candidate
US FDA Accepts NDA For Lenz’ Presbyopia Drop Candidate

Lenz Therapeutics announced Oct. 21 that the US FDA had accepted its new drug application (NDA) for LNZ100, a once-daily, preservative-free eye drop candidate for presbyopia. The FDA assigned a Pre...

11/14/2024
AllergyCataractClinical TrialCornealGlaucomaNewsletterPresbyopiaRetinaSurgical
Clinical Trial Updates for Ophthalmic Candidates, November 2024
Clinical Trial Updates for Ophthalmic Candidates, November 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

11/14/2024
CataractClinical TrialDealsDiagnosticDry EyeFundingGene TherapyGlaucomaIndustryInstrumentsMicroscopesNewsletterOCTPresbyopiaRegulationRetinaStudySurgical
November 2024 Ophthalmic News Briefs
November 2024 Ophthalmic News Briefs

Heidelberg Engineering announced Oct. 14 that the US FDA had granted 510(k) clearance to its Flex Module for the Spectralis diagnostic imaging platform. The Flex Module mounts the Spectralis to a m...

11/8/2024
BreakingCataractCornealDry EyeGlaucomaLaserPharmaPresbyopiaRefractiveRetinaRevenueSurgical
Q3-2024 Ophthalmic Revenue Roundup for AbbVie, Apellis, Glaukos, STAAR, and Lensar
Q3-2024 Ophthalmic Revenue Roundup for AbbVie, Apellis, Glaukos, STAAR, and Lensar

AbbVie, of North Chicago, Illinois, reported Oct. 30 that its Q3-2024 eye care net revenue was $525 million, a 13.5 percent decline (-11.2 percent cc) from $605 million in Q3-2023. Restasis revenue...

10/25/2024
BreakingPresbyopiaRegulation
US FDA Accepts NDA For Lenz’ Presbyopia Drop Candidate
US FDA Accepts NDA For Lenz’ Presbyopia Drop Candidate

Lenz Therapeutics announced Oct. 21 that the US FDA had accepted its new drug application (NDA) for LNZ100, a once-daily, preservative-free eye drop candidate for presbyopia. The FDA assigned a Pre...

10/25/2024
BreakingDealsGene TherapyPresbyopiaRefractiveRetina
Ocuphire Pharma Acquires Opus Genetics, Will Operate Under Opus Name
Ocuphire Pharma Acquires Opus Genetics, Will Operate Under Opus Name

Ocuphire Pharma announced Oct. 22 that it would acquire Opus Genetics in an all-stock transaction. The combined company will operate under the Opus name and will trade on the Nasdaq under the ticke...

10/18/2024
BreakingDealsPharmaPresbyopia
Orasis Licenses Qlosi Presbyopia Drops to Optus in Korea for $18 Million, Plus Royalties
Orasis Licenses Qlosi Presbyopia Drops to Optus in Korea for $18 Million, Plus Royalties

Orasis Pharmaceuticals announced Oct. 16 that it had licensed its Qlosi presbyopia drops to Optus Pharmaceuticals for the Korean market. Under the deal, Optus will pay upfront and milestone payment...

10/15/2024
AIDealsDiagnosticDigitalFundingMyopiaNewsletterPharmaPresbyopiaRetina
Orasis Leads Latest Ophthalmic Deals with $78 Million Financing
Orasis Leads Latest Ophthalmic Deals with $78 Million Financing

Orasis Pharmaceuticals led recent ophthalmic fundraising efforts with $78 million in Series D and structured capital to support the launch of Qlosi drops for presbyopia. Financing announced in the ...

10/15/2024
ESCRSEuropeMeetingNewsletterPresbyopia
ISOP Meeting Examines Importance of Patient Education and Predictable Outcomes
ISOP Meeting Examines Importance of Patient Education and Predictable Outcomes

Patient selection, education, and communication were emphasized throughout the International Society of Presbyopia’s 16th annual conference. The meeting, held Sept. 5 at the Hyatt Regency Hotel in ...

9/19/2024
Clinical TrialNewsletterOcular CancerPresbyopiaRetina
Clinical Trial Updates for Ophthalmic Candidates, September 2024
Clinical Trial Updates for Ophthalmic Candidates, September 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

8/21/2024
BiosimilarsCornealDealsDry EyeEuropeGene TherapyGenericsIndustryLow VisionNewsletterOcular CancerPharmaPresbyopiaRegulationRetina
August 2024 Ophthalmic News Briefs
August 2024 Ophthalmic News Briefs

Ireland-based Mallinckrodt announced Aug. 6 that its H.P. Acthar Gel single-dose prefilled SelfJect injector was available in the US. The US FDA approved the supplemental new drug application for t...

8/16/2024
BreakingPresbyopiaRegulation
Lenz Submits NDA to US FDA for LNZ100 Presbyopia Drop Candidate
Lenz Submits NDA to US FDA for LNZ100 Presbyopia Drop Candidate

Lenz Therapeutics announced Aug. 12 that it had submitted a new drug application to the US FDA for LNZ100, a once-daily, preservative-free eye drop candidate for presbyopia. Lenz, of San Diego, Cal...

7/23/2024
BiosimilarsCornealFundingGene TherapyMyopiaNewsletterPresbyopiaRetina
Beacon Leads Latest Ophthalmic Fundraising with $170 Million in Series B
Beacon Leads Latest Ophthalmic Fundraising with $170 Million in Series B

Beacon Therapeutics led recent ophthalmic fundraising efforts with $170 million in Series B funding to advance its candidates for retinal disease. Financing announced in the past four weeks totaled...

4/24/2024
Clinical TrialNewsletterPresbyopia
Lenz Reports Positive Topline Phase III Data in Presbyopia, Plans NDA Submission in Mid-2024
Lenz Reports Positive Topline Phase III Data  in Presbyopia, Plans NDA Submission in Mid-2024

Lenz Therapeutics reported April 3 positive topline results from its Phase III CLARITY trials of LNZ100 and LNZ101 for presbyopia. LNZ100 and LNZ101 are preservative free, single-use, once-daily ey...

4/5/2024
BreakingClinical TrialPresbyopia
Lenz Reports Positive Topline Phase III Data in Presbyopia, Plans NDA Submission in Mid-2024
Lenz Reports Positive Topline Phase III Data in Presbyopia, Plans NDA Submission in Mid-2024

Lenz Therapeutics reported April 3 positive topline results from its Phase III CLARITY trials of LNZ100 and LNZ101 for presbyopia. LNZ100 and LNZ101 are preservative-free, single-use, once-daily ey...

2/22/2024
CataractClinical TrialCornealDealsDiagnosticDry EyeGene TherapyGlaucomaIOLIndustryNewsletterPresbyopiaRegulationRetinaSurgical
February 2024 Ophthalmic News Briefs
February 2024 Ophthalmic News Briefs

Amneal Pharmaceuticals announced Jan. 10 that it had received US FDA approval for and launched generic fluorometholone eye drops. The product is indicated for the treatment of corticosteroid-respon...

1/23/2024
CornealDry EyeFundingNewsletterPresbyopiaRetina
Ji Xing Leads Latest Ophthalmic Fundraising with $162 Million in Series D Round
Ji Xing Leads Latest Ophthalmic Fundraising with $162 Million in Series D Round

China’s Ji Xing Pharmaceuticals led recent ophthalmic fundraising efforts with $162 million in Series D funding to advance its pipeline, which includes five ophthalmic candidates. Financing announc...

12/14/2023
Dry EyeGlaucomaNewsletterPharmaPresbyopiaRegulationRetina
FDA Approves 11 Ophthalmic Drug Products in 2023, Rejects Three More
FDA Approves 11 Ophthalmic Drug Products in 2023, Rejects Three More

2023 was a busy year for the US FDA in ophthalmology. Among the 11 drug products approved were the first two therapies in the US to treat geographic atrophy; two new drops for dry eye; and a second...

11/21/2023
NewsletterPharmaPresbyopia
Weekly Surgeon Poll, November 2023
Weekly Surgeon Poll, November 2023

11/21/2023
ChinaDealsDiagnosticDry EyeGene TherapyGenericsGlaucomaIndustryNewsletterPresbyopiaRegulationRetinaSurgical
November 2023 Ophthalmic News Briefs
November 2023 Ophthalmic News Briefs

Specialty pharma company Padagis announced Oct. 13 the launch of its brinzolamide ophthalmic suspension, a generic version of Novartis’ Azopt for glaucoma. Padagis, with offices in the US and Israe...

11/17/2023
BreakingDealsMergersPresbyopia
Lenz Plans Merger with Graphite Bio to Gain Nasdaq Listing, Advance Presbyopia Drop Candidate
Lenz Plans Merger with Graphite Bio to Gain Nasdaq Listing, Advance Presbyopia Drop Candidate

Privately held Lenz Therapeutics announced Nov. 15 that it had entered into an agreement to merge with Nasdaq-listed Graphite Bio in an all-stock transaction. The combined company would take the Le...

11/10/2023
BreakingIndustryLaserPresbyopiaRefractive
Ace Vision Group Names Rob Kissling, MD, as Chief Medical Officer
Ace Vision Group Names Rob Kissling, MD, as Chief Medical Officer

Laser company Ace Vision Group announced Nov. 1 that it had named Rob Kissling, MD, as chief medical officer. Most recently, Kissling served as vice president of clinical and medical affairs at Bau...

10/24/2023
NewsletterPresbyopiaRegulation
US FDA Approves Qlosi from Orasis as Eye Drop Treatment for Presbyopia
US FDA Approves Qlosi from Orasis as Eye Drop Treatment for Presbyopia

Orasis Pharmaceuticals announced Oct. 18 that the US FDA had approved Qlosi (pilocarpine hydrochloride 0.4%), a twice-daily eye drop for presbyopia. The company said it expected Qlosi, a preservati...

10/24/2023
IOLMeetingNewsletterPresbyopiaRefractive
ISOP Meeting Analyzes ‘Phacorestoration’ and ‘Presbyopia Botox’
ISOP Meeting Analyzes ‘Phacorestoration’ and ‘Presbyopia Botox’

The International Society of Presbyopia highlighted new treatment approaches that come with some interesting names. The conference was held Sept. 7 at the Vienna Marriott Hotel in Vienna, Austria. ...

10/20/2023
BreakingPharmaPresbyopia
US FDA Approves Presbyopia Drop Qlosi from Orasis
US FDA Approves Presbyopia Drop Qlosi from Orasis

Orasis Pharmaceuticals announced Oct. 18 that the US FDA had approved Qlosi (pilocarpine hydrochloride 0.4%), a twice-daily eye drop for presbyopia. The company said it expected Qlosi, a preservati...

8/25/2023
BreakingDiagnosticDry EyePresbyopiaRetinaRevenueSurgical
Q2-2023 Ophthalmic Revenue Roundup for AbbVie, Carl Zeiss Meditec, Alimera
Q2-2023 Ophthalmic Revenue Roundup for AbbVie, Carl Zeiss Meditec, Alimera

AbbVie, of North Chicago, Illinois, reported July 27 that Q2-2023 net revenue for its eye care products totaled $617 million, a 13.9 percent decline from $717 million in Q2-2022. Restasis revenue w...

7/25/2023
MeetingNewsletterOptometryPresbyopia
Presbyopia Drops, Aesthetics Draw High Interest at AOA Meeting
Presbyopia Drops, Aesthetics Draw High Interest at AOA Meeting

Dry eye products were a main attraction in the exhibit hall at the 126th annual congress of the American Optometric Association (AOA), while popular topics in sessions included premium IOLs, intrac...

7/25/2023
Dry EyeGlaucomaNewsletterPresbyopiaRegulationRetina
US FDA Target Action Dates for Ophthalmic Drug Candidates
US FDA Target Action Dates for Ophthalmic Drug Candidates

The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic prescription and biologic drug candidates and those classified as drug/device combin...

Want to Read the Full Article?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more